We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+5%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$40.3B
AUM Growth
+$535M
(+1.3%)
Cap. Flow
-$468M
Cap. Flow
% of AUM
-1.16%
Top 10 Holdings %
Top 10 Hldgs %
15.78%
Holding
2,279
New
170
Increased
711
Reduced
1,071
Closed
189
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$178M |
| 2 |
LyondellBasell Industries
LYB
|
+$133M |
| 3 |
AT&T
T
|
+$124M |
| 4 |
Stanley Black & Decker
SWK
|
+$101M |
| 5 |
Pfizer
PFE
|
+$93.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clorox
CLX
|
+$229M |
| 2 |
Gilead Sciences
GILD
|
+$164M |
| 3 |
Broadcom
AVGO
|
+$149M |
| 4 |
KeyCorp
KEY
|
+$145M |
| 5 |
Darden Restaurants
DRI
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.22% |
| 2 | Technology | 14.47% |
| 3 | Financials | 10.84% |
| 4 | Industrials | 9.01% |
| 5 | Consumer Discretionary | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1551
Ducommun
DCO
$2.59B
| $181K | ﹤0.01% |
4,161
-35
| -0.8% | -$1.65K |
|
|
PINC
1552
DELISTED
Premier
PINC
| $180K | ﹤0.01% |
6,519
-2,961
| -31% | -$84.5K |
|
1553
Genmab
GMAB
$21.2B
| $178K | ﹤0.01% |
4,678
-34,360
| -88% | -$1.37M |
|
|
AAMI
1554
Acadian Asset Management
AAMI
$3.17B
| $177K | ﹤0.01% |
8,463
-1,239
| -13% | -$27.6K |
|
1555
Aldeyra Therapeutics
ALDX
$82.6M
| $177K | ﹤0.01% |
+21,063
| New | +$208K |
|
|
BZUN
1556
Baozun
BZUN
$160M
| $174K | ﹤0.01% |
43,714
-291,084
| -87% | -$1.3M |
|
1557
FormFactor
FORM
$8.19B
| $174K | ﹤0.01% |
5,089
-874
| -15% | -$26.1K |
|
1558
Kelly Services Class A
KELYA
$566M
| $174K | ﹤0.01% |
9,855
-265
| -3% | -$4.58K |
|
1559
Ametek
AME
$53.2B
| $173K | ﹤0.01% |
1,070
-3,682
| -77% | -$538K |
|
1560
Rivian
RIVN
$22.1B
| $171K | ﹤0.01% |
10,292
+240
| +2% | +$3.35K |
|
|
AKRO
1561
DELISTED
Akero Therapeutics
AKRO
| $167K | ﹤0.01% |
3,584
-54,420
| -94% | -$2.49M |
|
1562
Western Digital
WDC
$150B
| $167K | ﹤0.01% |
5,826
-3,415
| -37% | -$95K |
|
|
AGS
1563
DELISTED
PlayAGS
AGS
| $166K | ﹤0.01% |
29,335
-5,077
| -15% | -$29.6K |
|
1564
Clarivate
CLVT
$1.2B
| $165K | ﹤0.01% |
17,320
+16,924
| +4,274% | +$143K |
|
|
SONX
1565
DELISTED
Sonendo, Inc.
SONX
| $163K | ﹤0.01% |
120,000
| – | – |
|
1566
Labcorp
LH
$26.3B
| $163K | ﹤0.01% |
787
+82
| +12% | +$15.9K |
|
|
RVNC
1567
DELISTED
Revance Therapeutics, Inc.
RVNC
| $163K | ﹤0.01% |
+6,443
| New | +$201K |
|
1568
Xencor
XNCR
$1.76B
| $163K | ﹤0.01% |
6,529
+61
| +0.9% | +$1.66K |
|
1569
Enterprise Financial Services Corp
EFSC
$2.25B
| $162K | ﹤0.01% |
4,153
+173
| +4% | +$7.15K |
|
1570
Kimco Realty
KIM
$15.2B
| $161K | ﹤0.01% |
8,140
+5,829
| +252% | +$110K |
|
|
CANO
1571
DELISTED
Cano Health, Inc.
CANO
| $160K | ﹤0.01% |
1,154
-581
| -33% | -$74.6K |
|
1572
Sierra Bancorp
BSRR
$526M
| $158K | ﹤0.01% |
9,333
-46
| -0.5% | -$757 |
|
1573
Nicolet Bankshares
NIC
$3.52B
| $157K | ﹤0.01% |
2,307
-8
| -0.3% | -$507 |
|
1574
Kinder Morgan
KMI
$68.4B
| $156K | ﹤0.01% |
9,080
-859
| -9% | -$14.6K |
|
1575
Keurig Dr Pepper
KDP
$43.3B
| $155K | ﹤0.01% |
4,960
-20
| -0.4% | -$657 |
|
Similar funds
Federated Hermes's Q2 2023 Portfolio in Review
As of Q2 2023, Federated Hermes held 2,279 positions worth $40.3B, up 1.3% from $39.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Federated Hermes's Q2 2023 filing shows 170 new, 711 increased, 1,071 reduced and 189 closed positions. Its largest new stake was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M. The largest sale was Clorox, an estimated $229M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- Federated Hermes's largest Q2 2023 buy was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M.
- Federated Hermes added most to Amgen in Q2 2023, an estimated $178M increase.
- Federated Hermes's biggest Q2 2023 reduction was Clorox, cutting an estimated $229M.
- Federated Hermes fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $55.4M.
- Federated Hermes's ten largest holdings make up 16% of its $40.3B portfolio in Q2 2023.
- Federated Hermes opened 170 new positions and closed 189 in Q2 2023.
- Federated Hermes's portfolio value rose 1.3% quarter-over-quarter to $40.3B.
Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.